BioCentury | Jun 6, 2011
Clinical News

AFP-464: Phase II started

...about 50 estrogen receptor-positive breast cancer patients. AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) markets Faslodex. Tigris Pharmaceuticals...
BioCentury | Oct 4, 2010
Company News

Tigris Pharmaceuticals board of directors update

Tigris Pharmaceuticals Inc. , Bonita Springs, Fla. Business: Cancer Appointed: Neil Flanzraich, chairman of ParinGenix Inc. , as executive chairman WIR Staff cancer...
BioCentury | Oct 4, 2010
Financial News

Tigris Pharmaceuticals completes venture financing

Tigris Pharmaceuticals Inc. , Bonita Springs, Fla. Business: Cancer Date completed: 9/28/10 Type: Venture financing Raised: $6.5 million Investors: Wexford Spectrum Investors; Sonostar Capital Partners; institutional investors; private investors WIR Staff cancer...
BioCentury | Apr 15, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Farnesyl transferase; geranylgeranyltransferase I (PGGT1B; GGTase I) A study in mice suggests that antagonizing both farnesyl transferase and GGTase I could help treat...
BioCentury | May 11, 2009
Clinical News

GGTI-2418: Phase I started

...South Florida (Tampa, Fla.) and Yale University (New Haven, Conn.) (see BioCentury, July 17, 2006). Tigris Pharmaceuticals...
BioCentury | Apr 20, 2009
Company News

Tigris Pharmaceuticals board of directors update

Tigris Pharmaceuticals Inc. , Bonita Springs, Fla. Business: Cancer Appointed: Pedro Granadillo, retired SVP of Eli Lilly and Co. , as chairman WIR Staff...
BioCentury | Mar 9, 2009
Clinical News

GGTI-2418: Phase I start

...South Florida (Tampa, Fla.) and Yale University (New Haven, Conn.) (see BioCentury, July 17, 2006). Tigris Pharmaceuticals...
BioCentury | Mar 6, 2008
Cover Story

Watching Cancer Glow Away

...the peptide's unknown target during treatment. Binh Nguyen, CMO and VP of clinical development at Tigris Pharmaceuticals...
...Switzerland sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France The Scripps Research Institute , La Jolla, Calif. Tigris Pharmaceuticals...
BioCentury | Feb 7, 2008
Targets & Mechanisms

Unraveling Bv8

...c-Kit)] Phase II ImClone IMC-3G3 antibody [PDGF receptor-a] Phase I ImClone Antibody [PDGF receptor-b] Preclinical Tigris Pharmaceuticals...
BioCentury | Feb 4, 2008
Clinical News

AFP-464: Phase I started

...In December, Tigris began a dose-escalation, European Phase I trial in about 35 patients. Tigris Pharmaceuticals Inc...
Items per page:
1 - 10 of 14
BioCentury | Jun 6, 2011
Clinical News

AFP-464: Phase II started

...about 50 estrogen receptor-positive breast cancer patients. AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) markets Faslodex. Tigris Pharmaceuticals...
BioCentury | Oct 4, 2010
Company News

Tigris Pharmaceuticals board of directors update

Tigris Pharmaceuticals Inc. , Bonita Springs, Fla. Business: Cancer Appointed: Neil Flanzraich, chairman of ParinGenix Inc. , as executive chairman WIR Staff cancer...
BioCentury | Oct 4, 2010
Financial News

Tigris Pharmaceuticals completes venture financing

Tigris Pharmaceuticals Inc. , Bonita Springs, Fla. Business: Cancer Date completed: 9/28/10 Type: Venture financing Raised: $6.5 million Investors: Wexford Spectrum Investors; Sonostar Capital Partners; institutional investors; private investors WIR Staff cancer...
BioCentury | Apr 15, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Farnesyl transferase; geranylgeranyltransferase I (PGGT1B; GGTase I) A study in mice suggests that antagonizing both farnesyl transferase and GGTase I could help treat...
BioCentury | May 11, 2009
Clinical News

GGTI-2418: Phase I started

...South Florida (Tampa, Fla.) and Yale University (New Haven, Conn.) (see BioCentury, July 17, 2006). Tigris Pharmaceuticals...
BioCentury | Apr 20, 2009
Company News

Tigris Pharmaceuticals board of directors update

Tigris Pharmaceuticals Inc. , Bonita Springs, Fla. Business: Cancer Appointed: Pedro Granadillo, retired SVP of Eli Lilly and Co. , as chairman WIR Staff...
BioCentury | Mar 9, 2009
Clinical News

GGTI-2418: Phase I start

...South Florida (Tampa, Fla.) and Yale University (New Haven, Conn.) (see BioCentury, July 17, 2006). Tigris Pharmaceuticals...
BioCentury | Mar 6, 2008
Cover Story

Watching Cancer Glow Away

...the peptide's unknown target during treatment. Binh Nguyen, CMO and VP of clinical development at Tigris Pharmaceuticals...
...Switzerland sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France The Scripps Research Institute , La Jolla, Calif. Tigris Pharmaceuticals...
BioCentury | Feb 7, 2008
Targets & Mechanisms

Unraveling Bv8

...c-Kit)] Phase II ImClone IMC-3G3 antibody [PDGF receptor-a] Phase I ImClone Antibody [PDGF receptor-b] Preclinical Tigris Pharmaceuticals...
BioCentury | Feb 4, 2008
Clinical News

AFP-464: Phase I started

...In December, Tigris began a dose-escalation, European Phase I trial in about 35 patients. Tigris Pharmaceuticals Inc...
Items per page:
1 - 10 of 14